252 related articles for article (PubMed ID: 18057307)
1. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients.
Caglar K; Yilmaz MI; Saglam M; Cakir E; Acikel C; Eyileten T; Yenicesu M; Oguz Y; Vural A; Carrero JJ; Axelsson J; Lindholm B; Stenvinkel P
Clin J Am Soc Nephrol; 2008 Jan; 3(1):61-8. PubMed ID: 18057307
[TBL] [Abstract][Full Text] [Related]
2. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.
Yilmaz MI; Sonmez A; Saglam M; Yaman H; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Yenicesu M; Mallamaci F; Zoccali C
Am J Kidney Dis; 2012 Feb; 59(2):177-85. PubMed ID: 22137672
[TBL] [Abstract][Full Text] [Related]
3. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.
Rastogi A
Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):322-42. PubMed ID: 24327730
[TBL] [Abstract][Full Text] [Related]
4. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.
Brandenburg VM; Schlieper G; Heussen N; Holzmann S; Busch B; Evenepoel P; Vanholder R; Meijers B; Meert N; Fassbender WJ; Floege J; Jahnen-Dechent W; Ketteler M
Nephrol Dial Transplant; 2010 Aug; 25(8):2672-9. PubMed ID: 20172849
[TBL] [Abstract][Full Text] [Related]
5. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.
Liu YL; Lin HH; Yu CC; Kuo HL; Yang YF; Chou CY; Lin PW; Liu JH; Liao PY; Huang CC
Ren Fail; 2006; 28(8):701-7. PubMed ID: 17162430
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with serum fetuin-A concentrations after long-term use of different phosphate binders in hemodialysis patients.
Lin HH; Liou HH; Wu MS; Huang CC
BMC Nephrol; 2016 Mar; 17():33. PubMed ID: 27007989
[TBL] [Abstract][Full Text] [Related]
7. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
8. Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study.
Ramos R; Moreso F; Borras M; Ponz E; Buades JM; Teixidó J; Morey A; Garcia C; Vera M; Doñate MT; de Arellano MR; Barbosa F; González MT
Perit Dial Int; 2007; 27(6):697-701. PubMed ID: 17984434
[TBL] [Abstract][Full Text] [Related]
9. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
10. Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients.
Lin YF; Chen YM; Hung KY; Chu TS; Kan WC; Huang CY; Lin SL; Kao TW; Huang JW; Chiang WC; Yen CJ; Tsai TJ; Wu KD; Wu MS
J Formos Med Assoc; 2010 Sep; 109(9):663-72. PubMed ID: 20863994
[TBL] [Abstract][Full Text] [Related]
11. Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study.
Barreto DV; Barreto Fde C; de Carvalho AB; Cuppari L; Draibe SA; Dalboni MA; Moyses RM; Neves KR; Jorgetti V; Miname M; Santos RD; Canziani ME
Nephron Clin Pract; 2008; 110(4):c273-83. PubMed ID: 19001830
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
Koizumi M; Fukagawa M
Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
[TBL] [Abstract][Full Text] [Related]
13. Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.
Ruggiero B; Trillini M; Tartaglione L; Rotondi S; Perticucci E; Tripepi R; Aparicio C; Lecchi V; Perna A; Peraro F; Villa D; Ferrari S; Cannata A; Mazzaferro S; Mallamaci F; Zoccali C; Bellasi A; Cozzolino M; Remuzzi G; Ruggenenti P; Kohan DE;
Am J Kidney Dis; 2019 Sep; 74(3):338-350. PubMed ID: 31027883
[TBL] [Abstract][Full Text] [Related]
14. Effects of sevelamer carbonate versus calcium acetate on vascular calcification, inflammation, and endothelial dysfunction in chronic kidney disease.
Mason DL; Godugu K; Nnani D; Mousa SA
Clin Transl Sci; 2022 Feb; 15(2):353-360. PubMed ID: 34599865
[TBL] [Abstract][Full Text] [Related]
15. Fetuin-A protects against atherosclerotic calcification in CKD.
Westenfeld R; Schäfer C; Krüger T; Haarmann C; Schurgers LJ; Reutelingsperger C; Ivanovski O; Drueke T; Massy ZA; Ketteler M; Floege J; Jahnen-Dechent W
J Am Soc Nephrol; 2009 Jun; 20(6):1264-74. PubMed ID: 19389852
[TBL] [Abstract][Full Text] [Related]
16. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.
Takei T; Otsubo S; Uchida K; Matsugami K; Mimuro T; Kabaya T; Akiba T; Nitta K
Nephron Clin Pract; 2008; 108(4):c278-83. PubMed ID: 18434749
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
Evenepoel P; Selgas R; Caputo F; Foggensteiner L; Heaf JG; Ortiz A; Kelly A; Chasan-Taber S; Duggal A; Fan S
Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate.
Cancela AL; Oliveira RB; Graciolli FG; dos Reis LM; Barreto F; Barreto DV; Cuppari L; Jorgetti V; Carvalho AB; Canziani ME; Moysés RM
Nephron Clin Pract; 2011; 117(1):c74-82. PubMed ID: 20689328
[TBL] [Abstract][Full Text] [Related]
19. Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them?
Floege J
Nephrol Dial Transplant; 2008 Oct; 23(10):3050-2. PubMed ID: 18625662
[No Abstract] [Full Text] [Related]
20. Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage 3-4.
Gulati A; Sridhar V; Bose T; Hari P; Bagga A
Int Urol Nephrol; 2010 Dec; 42(4):1055-62. PubMed ID: 20020207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
